Matrilysin-1 (MMP-T) and MMP-19 are expressed by Paget's cells in extramammary Paget's disease

Journal of Cutaneous Pathology

Volumn 31, Issue 7, 2004, Pages 483-491

  Kuivanen, Tiina ^a,b   Tanskanen, Maarit ^a   Jahkola, Tiina ^a   Impola, Ulla ^a   Asko Seljavaara, Sirpa ^a   Saarialho Kere, Ulpu ^a,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MIKKELI CENTRAL HOSPITAL   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; KALININ; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 19; SCLEROPROTEIN; STROMELYSIN; TENASCIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOCRINE GLAND; ARTICLE; CANCER CELL; CANCER INVASION; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PAGET SKIN DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CELL LINEAGE; COLLAGENASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LAMININ; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MIDDLE AGED; PAGET'S DISEASE, EXTRAMAMMARY; SKIN NEOPLASMS; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 3242746926     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2004.00211.x     Document Type: Article

References (42)

1. Zollo JD, Zeitouni NC. Roswell Park Cancer Institute experience with extramammary Paget's disease. Br J Dermatol 2000; 142: 59.
2. Ohnishi T, Watanabe S. The use of cytokeratins 7 and 20 in the diagnosis of primary and secondary extramammary Paget's disease. Br J Dermatol 2000; 142: 243.
3. Pierie JP, Choudry U, Muzikansky A, Finkelstein DM, Ott MJ. Prognosis and management of extramammary Paget disease and association with secondary malignancies. J Am Coll Surg 2003; 196: 45.
4. Kodama S, Kaneko T, Saito M, Yoshiya N, Honma S, Tanaka K. A clinicopathologic study of 30 patients with Paget's disease of the vulva. Gynecol Oncol 1995; 56: 63.
5. Tsuji T. Mammary and extramammary Paget's disease: expression of Ca15-3, Ka-93, Ca19-9, and CD44 in Paget cells and adjacent normal skin. Br J Dermatol 1995; 132: 7.
6. Ito Y, Watanabe S, Usui Y, Sahara R, Kitamura S, Matsukawa A. Expression of cytokeratin antigen 20 in perianal Paget's disease. Br J Dermatol 1999; 140: 1169.
7. Overall C, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657.
8. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534. [Review].
9. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003; 12: 109.
10. Vihinen P, Kahari V-M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 158.
11. Salmela MT, Karjalainen-Lindsberg M-L, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barret's oesophageal adenocarcinoma. Br J Cancer 2001; 85: 383.
12. Pendas AM, Knauper V, Puente XS, et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997; 272: 4281.
13. Sedlacek R, Mauch S, Kolb B, et al. Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology 1998; 198: 408.
14. Kolb C, Mauch S, Krawinkel U, Sedlacek R. Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not chronically, inflamed synovium. Exp Cell Res 1999; 250: 122.
15. Coldiron BM, Goldsmith BA, Robinson JK. Surgical treatment of extramammary Paget's disease. A report of six cases and a reexamination of Mohs micrographic surgery compared with conventional surgical excision. Cancer 1991; 67: 933.
16. Tanskanen M, Jahkola T, Asko-Seljavaara S, Jalkanen J, Isola J. HER-2 oncogene amplification in extramammary Paget's disease. Histopathology 2003; 42: 575.
17. Lohi J. Laminin-5 in the progression of carcinomas. Int J Cancer 2001; 94: 763. [Review].
18. Jahkola T, Toivonen T, Virtanen I, et al. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer 1998; 78: 1507.
19. Zhang C, Zhang P, Sung CJ, Lawrence WD. Overexpression of p53 is correlated stromal invasion in extramammary Paget's disease of the vulva. Hum Pathol 2003; 34: 880.
20. Saarialho-Kere UK, Kovacs SO, Pentland AP, Olerud JE, Welgus HC, Parks WC. Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J Clin Invest 1993; 92: 2858.
21. Saarialho-Kere UK, Pentland AP, Birkedal-Hansen H, Parks WC, Welgus HG. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest 1994; 94: 79.
22. Airola K, Johansson N, Kariniemi A-L, Kähäri V-M, Saarialho-Kere UK. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997; 109: 225.
23. Saarialho-Kere U, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995; 105: 190.
24. Pyke C, Romer J, Kallunki P, et al. The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994; 145: 782.
25. Tiitta O, Wahlstrom T, Paavonen J, et al. Enhanced tenascin expression in cervical and vulvar koilocytotic lesions. Am J Pathol 1992; 141: 907.
26. Murphy G, Cockett MI, Ward RV, Docherty AJP. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitive comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochemistry 1991; 277: 277.
27. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996; 28: 123.
28. Davies G, Jiang WG, Mason MD. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 2001; 7: 3289.
29. Stracke JO, Fosang AJ, Last K, et al. Matrix metalloproteinases 19 and 20 cleave aggregan and cartilage oligomeric matrix protein (COMP). FEBS Lett 2000; 478: 52.
30. Stracke JO, Hutton M, Stewart M, et al. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for the role as a potent membrane degrading enzyme. J Biol Chem 2000; 275: 14809.
31. Takata M, Hatta N, Takehara K. Tumour cells of extramammary Paget's disease do not show either p53 mutation or allelic loss at several selected loci implicated in other cancers. Br J Cancer 1997; 76: 904.
32. Takata M, Fujimoto A, Aoki H, et al. ErbB-2 overexpression but no activation of β-catenin gene in extramammary Paget's disease. J Invest Dermatol 1999; 113: 258.
33. O-charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA. O-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 2002; 38: 73.
34. Impola U, Toriseva M, Suomela S, et al. MMP-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer 2003; 103: 709.
35. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999; 18: 2883.
36. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin (MMP-7) expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001; 3: 459.
37. Djonov V, Hogger K, Sedlacek R, Laissue J, Draeger A. MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumors. J Pathol 2001; 195: 135.
38. Ala-aho R, Grenman R, Seth P, Kahari VM. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene 2002; 21: 1187.
39. Shieh S, Dee AS, Cheney RT, Frawley NP, Zeitouni NC, Oseroff AR. Photodynamic therapy for the treatment of extramammary Paget's disease. Br J Dermatol 2002; 146: 1000.
40. Parker LP, Parker JR, Bodurka-Bevers D, et al. Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol 2000; 77: 183.
41. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997; 11: 225.
42. Knauper V, Cowell S, Smith B, et al. The role of the C-terminal domain of the human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997; 272: 7608.